OKR

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Okapi Resources Limited

๐Ÿ‡ฆ๐Ÿ‡บ ASX

NULL STOCK

๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

N/A
Annual Growth

5 years average annual growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

2
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Okapi Resources Ltd. engages in the exploration and development of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2017-09-28. The firm's projects include Tallahassee Uranium, Rattler Uranium, Middle Lake, Newnham Lake, Perch, Lazy Edward Bay, Kelic Lake, Argo, Enmore Gold, and Maybell Uranium. The Tallahassee Uranium Project is located in central Colorado, United States, approximately 140 kilometers (km) southwest of Denver and 30km northwest of Canon City. The Rattler Uranium project is located approximately 85km north of Energy Fuels Incโ€™s White Mesa Uranium/Vanadium mill in Utah, United States. The Middle Lake Project comprises three claims totaling approximately 4,833 hectares in the Athabasca Basin, Canada. The Newnham Lake consists of 14 claims totaling approximately 16,940 hectares in the Athabasca Basin, Canada. The Maybell Uranium Project Located in Colorado, 5 km east of Maybell and 40 km west of Craig, the United States of America.

๐Ÿ“ˆ Performance

Price History

-47.50%

1M

All Time

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.10

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in OKR

0

๐Ÿ“Š Total Capital Earnings

$9K

๐Ÿ”ƒ Average investment frequency

13 weeks

๐Ÿ’ต Average investment amount

$7,799

โฐ Last time a customer invested in OKR

405 days
OKR investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

35 - 90

๐Ÿ™‹ Legal gender of investors

Female

Male

Pearlers who invest in OKR also invest in...

BPH Energy Ltd

BPH

BPH Energy Ltd. engages in investments in biotechnology and oil and gas exploration entities. The company is headquartered in Perth, Western Australia. The company went IPO on 2004-08-06. The firm holds a significant interest in an unlisted oil and gas exploration company. The Companyโ€™s principal activities include investments in various companies, which include Clean Hydrogen Technologies Corporation (Clean Hydrogen Technologies), Cortical Dynamics Limited (Cortical), Advent Energy Limited, and Molecular Discovery Systems Limited (MDSystems). Clean Hydrogen Technologies is a USA Delaware registered company with technology to produce clean hydrogen. The Advent Energy Limited is an unlisted oil and gas exploration and production company based in Perth, Western Australia. The Cortical is a medical device company focused on developing brain function monitors by employing theories and technologies in the field. MDSystems focuses on drug discovery and the validation of biomarkers for disease, therapy and diagnostics.

๐Ÿ™Œ Performance (5Yr p.a)

110.00%

๐Ÿ“Š Share price

$0.01 AUD

๐Ÿ’ธ FINANCIALS

Find Out More

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-02-11. The company owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Napperby Uranium, Yerelina and Mt Freeling, and Blueys-Inkheart. The Shoobridge Lithium Project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. The Anningie and Barrow Creek encompass eight exploration licenses over approximately 2,000 km2 in and around the Anningie and Barrow Creek tin-tantalum pegmatite fields in the Northern Territory. Napperby is an advanced uranium project within the central Northern Territory.

๐Ÿ™Œ Performance (5Yr p.a)

35.00%

๐Ÿ“Š Share price

$0.11 AUD

โ›๏ธ MINING

๐Ÿ“ˆ HIGH PRICE GROWTH

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

๐Ÿ™Œ Performance (5Yr p.a)

13.00%

๐Ÿ“Š Share price

$15.13 AUD

๐Ÿ‡ฆ๐Ÿ‡บ EX AUSTRALIA

๐Ÿ“ˆ HIGH PRICE GROWTH

โ›ณ๏ธ DIVERSIFIED

๐Ÿค– TECHNOLOGY

Appen Ltd. engages in the development of human-annotated datasets for machine learning and artificial intelligence. The company is headquartered in Chatswood, New South Wales and currently employs 992 full-time employees. The company went IPO on 2015-01-07. The firm is engaged in providing data services for deep learning and generative artificial intelligence (AI) systems. The firm operates through two segments: Global Services and New Markets. The Global Services represent the services that the Company provides to its five United States technology customers (Global customers) using the customer's data annotation platforms and tools. New Markets comprise Appen's data annotation platform and tools (Global Product), and the enterprise, government, and China business units. New Markets also include Quadrant geolocation and Point-of-Interest (POI) data capabilities. Its Annotation Platform is the platform that both customers and internal teams used to design, run and manage data annotation tasks. The firm serves various industries, including technology, automotive, financial services, healthcare, retail, and government agencies.

๐Ÿ™Œ Performance (5Yr p.a)

-18.08%

๐Ÿ“Š Share price

$2.05 AUD

๐Ÿค– TECHNOLOGY

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyโ€™s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

๐Ÿ™Œ Performance (5Yr p.a)

20.87%

๐Ÿ“Š Share price

$0.05 AUD

๐Ÿงฌ BIOTECHNOLOGY

๐Ÿ“ˆ HIGH PRICE GROWTH